Wolfe Research downgrades Ryan Specialty stock rating on valuation

Wolfe Research downgraded Ryan Specialty (RYAN) to Peerperform from Outperform, citing full valuation after the stock rose ~35% since the Q1 earnings release. The firm notes RYAN trades at a 17.8x earnings multiple vs peers at 16.7x, and ahead of its prior $39 target, while projecting street 2027 organic growth of 6.4% vs Wolfe’s 5.4% model. Offsetting the downgrade, the company expanded its share repurchase authorization by $300M (total available buybacks cited at $300M after exhaustion) and other analysts cited expectations of sizable buybacks and EPS rising to $2.10 (2026) and $2.50 (2027).

Analysis

RYAN’s setup is less about the downgrade itself and more about whether the market has already paid for a growth profile that is now slipping a little. At this valuation, incremental disappointment in organic growth matters more than the absolute print, because the stock is trading like a “quality compounder” while the next leg of upside now depends on buybacks and continued multiple support rather than accelerating fundamentals.

The competitive read-through is more interesting than the headline: specialty brokers with higher exposure to commercial P&C pricing softness are likely to see slower organic growth than diversified brokers such as MMC, AON, and BRO. If the rate environment remains softer for another 1-2 quarters, smaller underwriting/wholesale intermediaries can lose negotiating leverage first, which compresses take rates even if top-line premiums stay nominally healthy.

Near term, the buyback authorization should cushion downside and can mechanically support EPS over the next 12 months, but it does not solve the core issue of 2027 growth expectations being too optimistic. The main risk to a short is that management can buy enough stock to offset moderation in organic growth, keeping the stock range-bound rather than cheapening quickly. The thesis breaks if organic growth re-accelerates above consensus or if repurchase cadence meaningfully exceeds current assumptions over the next 2-3 quarters.

Key Decisions for Investors

• Short RYAN into strength over the next 1-4 weeks; use a tight risk limit above the post-rerating high, because downside is likely to be valuation-driven rather than fundamental until the next earnings cycle.
• Pair trade: long MMC or AON / short RYAN for 1-3 months. Own the more diversified, lower-valuation broker while fading the name with the most extended multiple and the most exposed growth expectations.
• If options liquidity is acceptable, buy a 3-6 month RYAN put spread rather than outright puts; the buyback program can blunt near-term downside, so structure for a moderate re-rating lower rather than a crash.
• Set an alert for any 2027 organic growth guide below consensus or a negative update on commercial P&C pricing in the next 1-2 quarters; that would be the cleanest catalyst for a second leg down.
• If the company signals materially faster repurchases than modeled, cover a portion of any short quickly — the stock can stay expensive longer if EPS is being artificially supported by capital return.